# US 2020/0206206 A1 · Methods Of Treating Fabry Patients Having Renal Impairment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206206 A1
- Document ID: US20200206206A1
- Status: Published application
- Kind: A1
- Application number: 16/817,908
- Filed: 2020-03-13
- Published: 2020-07-02
- Earliest claimed: 2017-05-30
- Assignees: Amicus Therapeutics, Inc.
- Applicants: Amicus Therapeutics, Inc.
- Inventors: Jeff Castelli; Elfrida Benjamin
- Web page: https://patentgrep.com/patent/US20200206206A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 13/12: of the kidneys
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

## Claims

### Claim 1

A method of stabilizing renal function in a patient diagnosed with Fabry disease and having renal impairment, the method comprising:
administering to the patient an effective amount of migalastat or salt thereof at a frequency of once every other day, and
wherein administration of a single dose of the migalastat or salt thereof to subjects with moderate renal impairment provides an increase in mean plasma migalastat AUC0-∞ by about 1.8-fold compared to healthy control subjects,
wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE), wherein the administration of the migalastat or salt thereof is effective to stabilize renal function in the patient and wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is an enzyme replacement therapy (ERT)-experienced patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has a proteinuria level of less than 100 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient has a proteinuria level of 100 to 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has a proteinuria level of greater than 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the migalastat or salt thereof is in a solid dosage form.

### Claim 8 (depends on 1)

The method of claim 1, wherein the migalastat or salt thereof is administered orally.

### Claim 9 (depends on 1)

The method of claim 1, wherein the migalastat or salt thereof is administered for at least 28 days.

### Claim 10 (depends on 1)

The method of claim 1, wherein the migalastat or salt thereof is administered for at least 6 months.

### Claim 11 (depends on 1)

The method of claim 1, wherein the migalastat or salt thereof is administered for at least 12 months.

### Claim 12 (depends on 1)

The method of claim 1, wherein administration of the effective amount of the migalastat or salt thereof to a group of patients having mild or moderate renal impairment provides a mean annualized rate of change in eGFRCKD-EPI of greater than −1.0 mL/min/1.73 m2.

### Claim 13 (depends on 1)

The method of claim 1, wherein administration of the effective amount of the migalastat or salt thereof to a group of patients having mild renal impairment provides a mean annualized rate of change in eGFRCKD-EPI of greater than −1.0 mL/min/1.73 m2.

### Claim 14 (depends on 1)

The method of claim 1, wherein administration of the effective amount of the migalastat or salt thereof to a group of patients having moderate renal impairment provides a mean annualized rate of change in eGFRCKD-EPI of greater than −1.0 mL/min/1.73 m2.

### Claim 15 (depends on 1)

The method of claim 1, wherein the effective amount is about 123 mg FBE.

### Claim 16 (depends on 1)

The method of claim 1, wherein the effective amount is about 123 mg of migalastat free base.

### Claim 17 (depends on 1)

The method of claim 1, wherein the effective amount is about 150 mg of migalastat hydrochloride.

### Claim 18 (depends on 1)

The method of claim 1, wherein the HEK assay amenable mutation is a mutation that is shown to have a relative increase of ≥1.20-fold and an absolute increase of ≥3.0% wild-type when the mutation is expressed in HEK-293 cells incubated in the presence of 10 μM migalastat compared to HEK-293 cells without migalastat.
